Senolytics combat COVID-19 in aging.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 37414986.
- Also identified by DOI 10.1038/s43587-023-00450-w and PMC identifier 10565907.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aging increases vulnerability to respiratory viral-infections, including SARS-CoV-2. Delval et al. established a causal role for age-related pre-existing senescent cells, in the severity of COVID-19 symptoms in an ageing hamster model. Selective depletion of senescent cells, using senolytics, was shown to mitigate the risk of severe COVID-19 symptoms linked to aging.
Medical subject headings
- COVID-19
- COVID-19 Drug Treatment
- Senotherapeutics